{"name":"IlDong Pharmaceutical Co Ltd","slug":"ildong-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"ildong.com","description":"IlDong Pharmaceutical Co Ltd is a South Korean pharmaceutical company with a diverse portfolio of drugs in various stages of development, focusing on innovative treatments and generics. The company has a strong presence in the domestic market and is expanding its global footprint through strategic partnerships and clinical trials.","hq":"Seoul","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Belviq 10mg","genericName":"Belviq 10mg","slug":"belviq-10mg","indication":"Other","status":"phase_1"},{"name":"Belviq 20mg","genericName":"Belviq 20mg","slug":"belviq-20mg","indication":"Other","status":"phase_1"},{"name":"Experimental drug","genericName":"Experimental drug","slug":"experimental-drug","indication":"Other","status":"phase_3"},{"name":"Placebo for Hydrochlorothiazide","genericName":"Placebo for Hydrochlorothiazide","slug":"placebo-for-hydrochlorothiazide","indication":"Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy","status":"phase_3"},{"name":"Placebo for Tamsulosin","genericName":"Placebo for Tamsulosin","slug":"placebo-for-tamsulosin","indication":"Control arm in Phase 3 trial for benign prostatic hyperplasia (comparison to Tamsulosin)","status":"phase_3"},{"name":"V - C+V - C","genericName":"V - C+V - C","slug":"v-c-v-c","indication":"Nutritional supplementation and deficiency prevention","status":"marketed"},{"name":"[Part1.2] IDG-16177","genericName":"[Part1.2] IDG-16177","slug":"part1-2-idg-16177","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Placebo(for Rosuvastatin 10mg)","genericName":"Placebo(for Rosuvastatin 10mg)","slug":"placebo-for-rosuvastatin-10mg","indication":"Control in clinical trials for cardiovascular diseases","status":"phase_3"},{"name":"Placebo(for Rosuvastatin 20mg)","genericName":"Placebo(for Rosuvastatin 20mg)","slug":"placebo-for-rosuvastatin-20mg","indication":"Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction)","status":"phase_3"},{"name":"Placebo(for Telmisartan 80mg)","genericName":"Placebo(for Telmisartan 80mg)","slug":"placebo-for-telmisartan-80mg","indication":"Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension)","status":"phase_3"},{"name":"Telmisartan/Amlodipine+Hydrochlorothiazide","genericName":"Telmisartan/Amlodipine+Hydrochlorothiazide","slug":"telmisartan-amlodipine-hydrochlorothiazide","indication":"Hypertension","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Besifovir dipivoxil","genericName":"Besifovir dipivoxil","slug":"besifovir-dipivoxil","indication":"Chronic hepatitis B infection","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"V - C - C+V","genericName":"V - C - C+V","slug":"v-c-c-v","indication":"Varicella (chickenpox) prevention","status":"marketed"}]}],"pipeline":[{"name":"Belviq 10mg","genericName":"Belviq 10mg","slug":"belviq-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Belviq 20mg","genericName":"Belviq 20mg","slug":"belviq-20mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Besifovir dipivoxil","genericName":"Besifovir dipivoxil","slug":"besifovir-dipivoxil","phase":"marketed","mechanism":"Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"Experimental drug","genericName":"Experimental drug","slug":"experimental-drug","phase":"phase_3","mechanism":"Experimental drug works by targeting a specific molecular pathway to produce a therapeutic effect.","indications":[],"catalyst":""},{"name":"Placebo for Hydrochlorothiazide","genericName":"Placebo for Hydrochlorothiazide","slug":"placebo-for-hydrochlorothiazide","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy"],"catalyst":""},{"name":"Placebo for Tamsulosin","genericName":"Placebo for Tamsulosin","slug":"placebo-for-tamsulosin","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 trial for benign prostatic hyperplasia (comparison to Tamsulosin)"],"catalyst":""},{"name":"Placebo(for Rosuvastatin 10mg)","genericName":"Placebo(for Rosuvastatin 10mg)","slug":"placebo-for-rosuvastatin-10mg","phase":"phase_3","mechanism":"Placebo does not have a pharmacological effect.","indications":["Control in clinical trials for cardiovascular diseases"],"catalyst":""},{"name":"Placebo(for Rosuvastatin 20mg)","genericName":"Placebo(for Rosuvastatin 20mg)","slug":"placebo-for-rosuvastatin-20mg","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":["Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction)"],"catalyst":""},{"name":"Placebo(for Telmisartan 80mg)","genericName":"Placebo(for Telmisartan 80mg)","slug":"placebo-for-telmisartan-80mg","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":["Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension)"],"catalyst":""},{"name":"Telmisartan/Amlodipine+Hydrochlorothiazide","genericName":"Telmisartan/Amlodipine+Hydrochlorothiazide","slug":"telmisartan-amlodipine-hydrochlorothiazide","phase":"phase_3","mechanism":"Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic.","indications":["Hypertension","Chronic stable angina"],"catalyst":""},{"name":"V - C - C+V","genericName":"V - C - C+V","slug":"v-c-c-v","phase":"marketed","mechanism":"V-C-C+V is a combination vaccine containing inactivated varicella-zoster virus and other viral components designed to provide immunization against varicella (chickenpox) and related viral infections.","indications":["Varicella (chickenpox) prevention","Immunization against varicella-zoster virus"],"catalyst":""},{"name":"V - C+V - C","genericName":"V - C+V - C","slug":"v-c-v-c","phase":"marketed","mechanism":"V-C+V-C is a combination product containing vitamins and minerals that provides nutritional supplementation.","indications":["Nutritional supplementation and deficiency prevention"],"catalyst":""},{"name":"[Part1.2] IDG-16177","genericName":"[Part1.2] IDG-16177","slug":"part1-2-idg-16177","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWkpvT1pGOEZIN0RGUzBYSnIySUVXZ1ZwSktrM3RIZVRTMTJzMHB4QnhSb3JKUTBaTDhTS2lNRWdrLVBJY0lWVG84NzVKZHBSWUZER0NKWVhpbnlucjJxMzVDbnc0ZGRUbmk0VHM3aEZOZ1RzSDZLaUItZEZBb0V4ddIBlAFBVV95cUxQb0lDODZPemhRVkhZWHd2bXBMSVZQYXp6Ukx0TXAxTGZCb2Zmb3VoOExEbjdzYlRsUTQzT3VTT3BpQWNRMWVEeXZUWTJ1MG1fUlBBczFWVFdIQ3N0ZlpvLS1vQXdPUFo4dnUwSDlGRTVSR2FNa3RsdjFSUWl6eldFbUZNRGxVRzV3c1U1Qk9wVjN0RVBU?oc=5","date":"2026-04-06","type":"pipeline","source":"Chosunbiz","summary":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ - Chosunbiz","headline":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQb0lDODZPemhRVkhZWHd2bXBMSVZQYXp6Ukx0TXAxTGZCb2Zmb3VoOExEbjdzYlRsUTQzT3VTT3BpQWNRMWVEeXZUWTJ1MG1fUlBBczFWVFdIQ3N0ZlpvLS1vQXdPUFo4dnUwSDlGRTVSR2FNa3RsdjFSUWl6eldFbUZNRGxVRzV3c1U1Qk9wVjN0RVBU0gGUAUFVX3lxTFBvSUM4Nk96aFFWSFlYd3ZtcExJVlBhenpSTHRNcDFMZkJvZmZvdWg4TERuN3NiVGxRNDNPdVNPcGlBY1ExZUR5dlRZMnUwbV9SUEFzMVZUV0hDc3RmWm8tLW9Bd09QWjh2dTBIOUZFNVJHYU1rdGx2MVJRaXp6V0VtRk1EbFVHNXdzVTVCT3BWM3RFUFQ?oc=5","date":"2026-04-06","type":"pipeline","source":"Chosunbiz","summary":"Korea pharma shifts to external hires to power R&D and global expansion - CHOSUNBIZ - Chosunbiz","headline":"Korea pharma shifts to external hires to power R&D and global expansion - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1jeE1jYnpfaHBuMlpkSGN2c2RmclVaYmZCRVl4S0t5bkJXMjFsTFlMNnh3OUVqWlFLVVpObU1OdzAxQ0x1c2ZCdDlMd2JXS0JxdGJwQk9ObzBCMWFjM21hb3g3MElFZUtGei1ia3dB?oc=5","date":"2026-01-23","type":"pipeline","source":"KED Global","summary":"S.Korea speeds homegrown weight-loss drug development led by Hanmi Pharm - KED Global","headline":"S.Korea speeds homegrown weight-loss drug development led by Hanmi Pharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNWUQteENvX2l3YnZLZmxObzZ1dlQtWmNPYmM3TFNvOXRPMW52a3NvYnU1LXFQSGg2NEw3amlpQVo2dlJFdUtLRmxzNTdkWENWNnhjaXM5aENCMjdjbTNQVDgwRmdmbHpSXy1obHkwTmhqMXRibzBJS3dUcmJjTzJnT3RmRzdGVE1iNEV6bV94S09mNVlpMFp5ZTZIZ0d3MTA?oc=5","date":"2024-06-11","type":"pipeline","source":"BioWorld News","summary":"Abtis tapping ADC market with Claudin18.2-targeting AT-211 - BioWorld News","headline":"Abtis tapping ADC market with Claudin18.2-targeting AT-211","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5mcF9FOFEzN2tvNmJSSFpoZUNxbWpsNEQzUFVjSExnNWdfaDhsdHFaeVBKZ2thRmlocy1SLXRET3JvbHlCb0xKa3U1VmFSZ0taMUJrNFdGekNVbVpoeWNnN09nQ1l4NTFmeUJCWHl3?oc=5","date":"2023-10-06","type":"pipeline","source":"KED Global","summary":"Ildong Pharma to spin off R&D subsidiary in Nov - KED Global","headline":"Ildong Pharma to spin off R&D subsidiary in Nov","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5RR2dGVW9WZWpTaVhGZ29ZLTBqUkxvM0FwX2FRUmkxRVBpaWRyeFBvemtoRmlXOG1RZWljM0w4OG8zNkhaTDNGSGl0cHZYZ01mNnZTRlU5VDdYWDc0RlBORmRWQnVWeDFwcF9icVVB?oc=5","date":"2022-06-24","type":"pipeline","source":"KED Global","summary":"Pharma companies jump into $3 bn pet care market - KED Global","headline":"Pharma companies jump into $3 bn pet care market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5STFJvZjBjeUVfMTZtNnhzX243NDNHdkRtWUxtaDg5dm9NSkFsNUVPUUR0RklNNkxsSzFnb0tPMGJVOGU2UDk2cjlmbmd3ZU1zZmNxM3pkTjBqWERlZkZpQ0RtTG9ZcDRYajJITnBaenU0QQ?oc=5","date":"2014-10-23","type":"pipeline","source":"Businesskorea","summary":"73-year-old Pharmaceutical Company to Manufacture Anti-cancer Drugs in Saudi Arabia - Businesskorea","headline":"73-year-old Pharmaceutical Company to Manufacture Anti-cancer Drugs in Saudi Arabia","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_1":3,"marketed":3,"phase_3":7},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}